Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


David Filmore

Executive Editor

Rochester, NY
David Filmore has been covering the health care sector as a writer and editor for 16 years. He specializes in devices and diagnostics, particularly focusing on the regulatory and reimbursement dynamics that impact a company’s ability to succeed in the marketplace. Originally trained as a scientist, Dave enjoys dissecting technical topics to reach a core understanding. As a writer and editor, he relishes communicating that understanding, important context and key takeaways for practical use by the reader. Dave has led operations or served on the staff of “The Gray Sheet” for more than a decade, and now oversees Regulatory and Policy content for the new Medtech Insight. Previously, he was an editor with the American Chemical Society, producing content for professionals in the pharmaceutical industry and analytical instrumentation space. He has also worked in the pharma industry, and has a degree in chemistry. Dave lives with his wife and two kids in Rochester, NY.
Set Alert for Articles By David Filmore

Latest From David Filmore

Lab Sector Vs. CMS Battle Heats Up As Medicare Agency Moves Forward With 2018 Rates

Test-makers and labs say the agency is missing large swaths of the market in making its "market-based" lab payment calculation, but CMS stands by its data, and finalized 2018 lab fee schedule rates. Could next steps be in Congress, or the courts?

Commercial Market Access

A New York Minute: US FDA Leverages State's Health Department To Expedite NGS Reviews

The agency authorized a next-generation sequencing tumor profiling system that leverages the New York State Department of Health to speed future clearances.

Regulation In Vitro Diagnostics

US Approvals Analysis: Original PMA Slowdown, De Novo Upswing Among Recent Trends

The volume of original PMAs coming to US FDA for review is down recently, while panel-track supplement, de novo and 510(k) volumes are up. October, meanwhile, was a relatively light month for novel device approvals, but better-than-average for 510(k) clearances.

Approvals Innovation

Device Week, Nov. 9, 2017 – US Supreme Court Preview

On this week's podcast, we discuss some cases that might come up in the current session of the US Supreme Court and have an important impact on the device industry – in the realm of patent reviews, and consumer and state lawsuits.

Legal Issues Commercial

The Clock's Ticking: Tracking Global Regulatory Deadlines

The global regulatory environment for devices and diagnostics is rapidly evolving, with new frameworks, rules and directives rolling out around the world. To help keep up during this period of fundamental change, Medtech Insight has launched a new interactive timeline.

Regulation Compliance

US Regulatory Reads, October 2017: Horror Stories, Super Offices And Artificial Intelligence

Our "terrifying tales" of US FDA inspections that went awry attracted, by far, the most readers last month. Also popular in October: Medtech Insight's reporting on the US agency's move to bring its device evaluation, compliance and surveillance activities all under one roof, and our deep-dive look at the promise and challenges of applying artificial intelligence to quality operations.

Regulation FDA
See All